Investigational Drug Information for AZD9291
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug AZD9291?
AZD9291 is an investigational drug.
There have been 85 clinical trials for AZD9291.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 18th 2015.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are twenty-three US patents protecting this investigational drug and three hundred and eighteen international patents.
Summary for AZD9291
| US Patents | 23 |
| International Patents | 318 |
| US Patent Applications | 61 |
| WIPO Patent Applications | 40 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-09-18) |
| Vendors | 79 |
Recent Clinical Trials for AZD9291
| Title | Sponsor | Phase |
|---|---|---|
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | National Cancer Institute (NCI) | Phase 2 |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Southwest Oncology Group | Phase 2 |
| A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) | AstraZeneca | Phase 2 |
Clinical Trial Summary for AZD9291
Top disease conditions for AZD9291
Top clinical trial sponsors for AZD9291
US Patents for AZD9291
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD9291 | See Plans and Pricing | 2-(2,4,5-substituted-anilino)pyrimidine compounds | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD9291 | See Plans and Pricing | AZD9291 intermediate and preparation method therefor | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN) | See Plans and Pricing |
| AZD9291 | See Plans and Pricing | Pharmaceutical compositions comprising AZD9291 | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD9291
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD9291 | Argentina | AR087336 | 2031-07-27 | See Plans and Pricing |
| AZD9291 | Argentina | AR115019 | 2031-07-27 | See Plans and Pricing |
| AZD9291 | Australia | AU2012288626 | 2031-07-27 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
